Back to results
US 2006/0189584 A1Published application
Pharmaceutical combinations
AssigneeAstraZeneca AB
InventorsJohn Dixon, Robert Humphries, Alexander Nicol
Life of this patent
Estimating the term…
Abstract
The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. The combinations comprise a compound of formula (I) or a pharmaceutically acceptable derivative thereof; formula (I), and another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof.
Claims38
A kit of parts comprising:
- (a) a compound of formula (I)
- wherein:
- R is CH2OH or O(CH2)2OH;
- R1 is C3-4 alkyl optionally substituted by three halogen atoms;
- R2 is phenyl or 3,4-difluorophenyl;
- or a pharmaceutically acceptable derivative thereof, (component a);
- and
- (b) another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof (component b);
- where components (a) and (b) are each provided in a form (which may be the same or different) that is suitable for administration in conjunction with each other.
6 more elements
A pharmaceutical formulation comprising:
- (a) a compound of formula (I) or a pharmaceutically acceptable derivative thereof;
- and
- (b) another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof;
- in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
1 more element
The use of:
- (a) a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier;
- and
- (b) a pharmaceutical formulation comprising another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,
- in therapy.
1 more element
The use of:
- (a) a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier;
- and
- (b) a pharmaceutical formulation comprising another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,
- in the treatment of thrombosis
1 more element
A method of treating thrombosis which comprises administering to a person suffering from, or susceptible to such a condition:
- (a) a pharmaceutical formulation comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, and
- (b) a pharmaceutical formulation comprising another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
A compound of formula (I) which is:
- in combination with aspirin, clopidogrel, ticlopidine, dipyridamole, a GPIIb/IIIa antagonist, a direct thrombin inhibitor, a prodrug of a direct thrombin inhibitor, warfarin, a factor Xa inhibitor, heparin, a low molecular weight heparin, tissue plasminogen activator, tenecteplase, or any combination thereof
A compound of formula (I) which is:
- in combination with aspirin, clopidogrel, ticlopidine, dipyridamole, a GPIIb/IIIa antagonist, a direct thrombin inhibitor, a prodrug of a direct thrombin inhibitor, warfarin, a factor Xa inhibitor, heparin, a low molecular weight heparin, tissue plasminogen activator, tenecteplase, or any combination thereof.
A compound of formula (I) which is:
- in combination with aspirin, clopidogrel, ticlopidine, dipyridamole, a GPIIb/IIIa antagonist, a direct thrombin inhibitor, a prodrug of a direct thrombin inhibitor, warfarin, a factor Xa inhibitor, heparin, a low molecular weight heparin, tissue plasminogen activator, tenecteplase, or any combination thereof.
A compound of formula (I) which is:
- in combination with aspirin, clopidogrel, ticlopidine, dipyridamole, a GPIIb/IIIa antagonist, a direct thrombin inhibitor, a prodrug of a direct thrombin inhibitor, warfarin, a factor Xa inhibitor, heparin, a low molecular weight heparin, tissue plasminogen activator, tenecteplase, or any combination thereof.
Dependencies are inferred from the claim text.